AOD-9604

⏱ Half-Life

Short duration profile

AOD-9604 demonstrates a short half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.

⚡ Onset Characteristics

Moderate measurable response

Onset is observed as moderate — a property that influences how researchers structure comparative studies versus other compounds in the metabolic research category.

🧠 Key Notes

What makes it distinct

• 01Comprises the lipolytic region of the GH molecule (residues 176-191)
• 02Investigated for fat-metabolism effects independent of IGF-1 elevation
• 03Does not appear to influence blood glucose or insulin sensitivity in published research

🧬 Mechanism of Action

How it works

AOD-9604 is a 15-amino-acid synthetic peptide corresponding to the C-terminal region of human growth hormone (hGH 176-191), which contains the lipolytic activity of the full hormone. It stimulates lipolysis — the breakdown of triglycerides into free fatty acids and glycerol — by mimicking the natural fat-metabolism signalling of GH without activating the broader GH receptor cascade. Unlike full-length GH or GH-secretagogues, AOD-9604 does not significantly raise IGF-1, insulin, or blood glucose, isolating the fat-oxidation pathway. Research also describes interactions with the beta-3-adrenergic receptor and modulation of adipose-tissue gene expression toward lipolytic profiles.

✨ Documented Benefits

What the research shows it supports

🔍 Research Insights

What the literature shows

🧪 Typical Research Use Cases

Where it appears in study design

📚 References

Peer-reviewed literature

Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.

1. [01]

   Ng, F. M. et al. (2000). Metabolic effects of a synthetic fragment of human growth hormone. International Journal of Molecular Medicine, 6(3), 233–239.

   International Journal of Molecular Medicine ↗
2. [02]

   Heffernan, M. et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology, 142(11), 5182–5189.

   Endocrinology ↗
3. [03]

   Gubler, M. et al. (2007). AOD9604, a peptide fragment of growth hormone, exhibits significant lipolytic effects in vitro and in vivo. Metabolism, 56(10), 1372–1379.

   Metabolism ↗
4. [04]

   Gaudriault, G. et al. (2005). Assessment of the cardiac effects of a growth hormone fragment (AOD-9604) in vitro and in vivo. Growth Hormone & IGF Research, 15(2), 116–122.

   Growth Hormone & IGF Research ↗